Pulling SEC filings + quote and writing the call…

Septerna, Inc.
Next earnings Aug 10, 2026 · consensus $-0.47 EPS, $16.3M rev
Last earnings +12.9% on 2026-05-11
Revenue grew 4174.5% YoY; but unprofitable (net margin -106.4%).
Revenue (FY2025) $46.0M · FY2025
Septerna, Inc. shows $46.0M in FY2025 revenue (+4174.5% YoY), a -106.4% net margin, and -12.8% ROE.
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $151K | $1.07M | $46.0M |
| Gross profit | — | — | — |
| Operating income | $2.08M | -$80.8M | -$68.3M |
| Net income | $4.18M | -$71.8M | -$48.9M |
| Diluted EPS | $0.29 | -$7.26 | -$1.10 |
| Net margin | 2768.2% | -6678.9% | -106.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001984086, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 4:54:51 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 10 sales
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Exercise | 10.5K @ $2.76 | $29.1K |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Exercise | 4.47K @ $11.70 | $52.3K |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sell | 8.00K @ $35.10 | $281K |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sell | 7.00K @ $35.97 | $252K |
| 2026-06-12 | Shaikhly Samira Chief People Officer | Exercise | 6.25K @ $11.70 | $73.1K |
| 2026-06-12 | Shaikhly Samira Chief People Officer | Sell | 6.25K @ $35.08 | $219K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Exercise | 4.36K @ $1.55 | $6.75K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Exercise | 943.00 @ $2.76 | $2.60K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Exercise | 637.00 @ $2.76 | $1.76K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Sell | 1.70K @ $27.78 | $47.2K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Sell | 1.35K @ $28.79 | $38.8K |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Sell | 2.89K @ $29.66 | $85.7K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1043 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.